AnaptysBio Inc
ANAB24.340USD
-0.350-1.42%
交易中 （美東）報價延遲15分鐘
739.64M總市值
虧損本益比TTM
關於 AnaptysBio Inc 公司
AnaptysBio, Inc. 是一家專注於提供免疫療法的臨牀階段生物技術公司。該公司正在開發免疫細胞調節劑，包括兩種用於自身免疫和炎症疾病的檢查點激動劑：其 PD-1 激動劑 rosnilimab，正在進行治療類風溼性關節炎的 2b 期試驗和治療潰瘍性結腸炎的 2 期試驗；其 BTLA 激動劑 ANB032，正在進行治療特應性皮炎的 2b 期試驗。該公司的臨牀前免疫細胞調節劑產品組合包括抗 CD122 拮抗劑抗體 ANB033 和 BDCA2 調節劑抗體 ANB101，用於治療自身免疫和炎症疾病。此外，該公司還開發了兩種可供對外授權的細胞因子拮抗劑：imsidolimab，一種抗 IL-36R 拮抗劑，目前處於第 3 階段，用於治療全身性膿皰型銀屑病或 GPP；etokimab，一種抗 IL-33 拮抗劑，用於治療呼吸系統疾病，已準備好進行第 2/3 階段。
公司簡介
公司代碼ANAB
公司名稱AnaptysBio Inc
上市日期Jan 26, 2017
CEOMr. Daniel R. Faga
員工數量136
證券類型Ordinary Share
年結日Jan 26
公司地址10770 Wateridge Circle, Suite 210
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92121
電話18583626295
網址https://www.anaptysbio.com/
公司代碼ANAB
上市日期Jan 26, 2017
CEOMr. Daniel R. Faga
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
436.47K
+0.39%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
63.34K
+10.52%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
11.86K
+161.67%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
9.93K
+154.62%
Mr. John A. Orwin
Mr. John A. Orwin
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
9.37K
+180.81%
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
9.36K
+438.05%
Mr. Hollings C. Renton
Mr. Hollings C. Renton
Independent Director
Independent Director
4.96K
--
Mr. Dennis M. Mulroy, CPA
Mr. Dennis M. Mulroy, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Paul F. Lizzul, M.D., Ph.D.
Dr. Paul F. Lizzul, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Dennis Fenton, Ph.D.
Dr. Dennis Fenton, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
436.47K
+0.39%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
63.34K
+10.52%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
11.86K
+161.67%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
9.93K
+154.62%
Mr. John A. Orwin
Mr. John A. Orwin
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
9.37K
+180.81%
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
9.36K
+438.05%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月4日 週三
更新時間: 6月4日 週三
持股股東
股東類型
持股股東
持股股東
佔比
EcoR1 Capital, LLC
26.82%
First Light Asset Management, LLC
15.77%
Point72 Asset Management, L.P.
8.06%
BlackRock Institutional Trust Company, N.A.
6.24%
Tang Capital Management, LLC
5.26%
Other
37.85%
持股股東
持股股東
佔比
EcoR1 Capital, LLC
26.82%
First Light Asset Management, LLC
15.77%
Point72 Asset Management, L.P.
8.06%
BlackRock Institutional Trust Company, N.A.
6.24%
Tang Capital Management, LLC
5.26%
Other
37.85%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
54.45%
Hedge Fund
35.32%
Investment Advisor
28.78%
Research Firm
10.05%
Venture Capital
5.17%
Corporation
2.80%
Individual Investor
2.39%
Bank and Trust
0.20%
Pension Fund
0.11%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
357
40.92M
139.28%
-6.37M
2025Q1
366
43.04M
145.37%
-6.68M
2024Q4
347
37.49M
122.64%
-3.24M
2024Q3
334
34.49M
113.52%
-2.22M
2024Q2
323
30.70M
111.87%
-5.39M
2024Q1
311
29.59M
108.34%
-6.31M
2023Q4
311
30.68M
115.35%
-5.19M
2023Q3
313
31.58M
118.68%
-4.34M
2023Q2
316
31.50M
118.55%
-4.32M
2023Q1
320
32.34M
119.61%
-5.26M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
EcoR1 Capital, LLC
7.88M
26.82%
--
--
Apr 01, 2025
First Light Asset Management, LLC
4.63M
15.77%
-19.47K
-0.42%
Mar 31, 2025
Point72 Asset Management, L.P.
2.37M
8.06%
+677.00K
+40.03%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.83M
6.24%
-174.28K
-8.68%
Mar 31, 2025
Tang Capital Management, LLC
1.55M
5.26%
+214.27K
+16.10%
Mar 31, 2025
The Vanguard Group, Inc.
1.51M
5.16%
-326.42K
-17.73%
Mar 31, 2025
Boxer Capital Management, LLC
1.30M
4.42%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.24M
4.24%
-1.05M
-45.76%
Mar 31, 2025
Sofinnova Investments, Inc
1.16M
3.95%
+1.03M
+772.68%
Mar 31, 2025
BofA Global Research (US)
1.14M
3.89%
+1.13M
+6273.39%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco Dorsey Wright Healthcare Momentum ETF
1.18%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
ALPS Medical Breakthroughs ETF
0.44%
Tema Oncology ETF
0.37%
SPDR S&P Biotech ETF
0.15%
iShares Micro-Cap ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Biotechnology ETF
0.06%
查看更多
Invesco Dorsey Wright Healthcare Momentum ETF
佔比1.18%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.85%
ALPS Medical Breakthroughs ETF
佔比0.44%
Tema Oncology ETF
佔比0.37%
SPDR S&P Biotech ETF
佔比0.15%
iShares Micro-Cap ETF
佔比0.1%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.09%
ProShares Ultra Nasdaq Biotechnology
佔比0.07%
Invesco Nasdaq Biotechnology ETF
佔比0.07%
iShares Biotechnology ETF
佔比0.06%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
